| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO | C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN | /s/ Avraham S. Adler, Attorney-in-Fact | 19 May 2025 | 0001578852 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PTCT | Common Stock | Options Exercise | $49,556 | +1,929 | +1.9% | $25.69 | 105,830 | 15 May 2025 | Direct | F1 |
| transaction | PTCT | Common Stock | Sale | $89,081 | -1,929 | -1.8% | $46.18 | 103,901 | 15 May 2025 | Direct | F1, F2 |
| transaction | PTCT | Common Stock | Options Exercise | $22,684 | +883 | +0.85% | $25.69 | 104,784 | 16 May 2025 | Direct | F1 |
| transaction | PTCT | Common Stock | Sale | $40,636 | -883 | -0.84% | $46.02 | 103,901 | 16 May 2025 | Direct | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PTCT | Stock Option (Right to Buy) | Options Exercise | $0 | -1,929 | -6.3% | $0.000000 | 28,595 | 15 May 2025 | Common Stock | 1,929 | $25.69 | Direct | F1, F4 |
| transaction | PTCT | Stock Option (Right to Buy) | Options Exercise | $0 | -883 | -3.1% | $0.000000 | 27,712 | 16 May 2025 | Common Stock | 883 | $25.69 | Direct | F1, F4 |
| Id | Content |
|---|---|
| F1 | This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. |
| F2 | This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.61 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| F3 | This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.19 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| F4 | This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. |